MedTrace Logo

Early Beta Blocker Administration in STEMI Patients With SCAI B Status

NCT06967194 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-05-28

No results posted yet for this study

Summary

This study is looking at how a medication called beta-blockers (metoprolol) affects patients with a heart attack (STEMI) who are in the cardiac intensive care unit.

When patients are admitted to the unit, they will be randomly placed in one of two groups. One group will get the metoprolol medication, and the other will receive a placebo (a harmless pill that looks like the real medication). All other treatments will be the same for both groups.

During the study, which is 72 hours long, patients will be monitored for blood pressure, heart rate, and lactate levels alterations.

The main goal is to see if the medication helps improve patients condition or prevent it from getting worse. patients safety is a top priority, and if needed, the doctors can stop the study at any time if there are concerns.

Conditions

  • ST Segment Elevation Myocardial Infarction (STEMI)
  • Cardiogenic Shock Post Myocardial Infarction

Interventions

DRUG

Metoprolol (MET)

Administration of metoprolol 25 mg twice daily

DRUG

Plcacebo

Administration of matching placebo

Sponsors & Collaborators

  • Tel-Aviv Sourasky Medical Center

    lead OTHER_GOV

Principal Investigators

  • Yishay Szekely, MD · Tel-Aviv Sourasky Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-21
Primary Completion
2027-05-31
Completion
2027-06-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06967194 on ClinicalTrials.gov